New drug entity

An alternative approach involves testing of new drug entities on whole-cell systems and measuring effects on integrated cellular pathways. Favorable phenotypic responses are identified with this approach that may better produce alteration of multicomponent disease processes. 

The most serious disadvantage of the prodrug approach to controlled sustained delivery is that extensive development must be undertaken to find the correct chemical modification for a specific drug. Additionally, once a prodrug is formed, it is a new drug entity and, therefore, requires extensive and costly studies to determine safety and efficacy. 

The standard toxicological data package for any new drug entity typically evaluates... 

The NIH has set up a consortium called the Molecular Libraries Screening Center Network (MLSCN), which performs HTS on assays provided by the research community. It currently has more than 100,000 chemically diverse compounds. This is an initiative of the Molecular Libraries Roadmap, which also has another two components Cheminformatics and Technology Development. The aim is to generate a comprehensive database of chemical compounds and their bioactivities to enhance the capability for the development of new drug entities. 

Seeing a chemical agent proceed through the maze required for FDA approval as a new drug entity makes one truly appreciative of the extensive expertise required at every stage. It is impossible to credit all of those involved in this 12-year quest. One thing is certain. Without collaborative skills at every level, a strong perseverance to continue... 

This book consists of 800 examination-type MCQs (300 of which are new questions and over 30 new drug entities are included). The questions are practice oriented and are intended to assess knowledge, evaluative and analytical skills, and ability to apply that knowledge in clinical practice. 

Full Validation. Full validation is important when developing and implementing a bioanalytical method for the first time, for a new drug entity, and if metabolites are added to an existing assay for quantification. 

As new drug entities must be usually be prepared as single enantiomers, and as many contain one or more heterocyclic or carbocyclic rings, there is an increased emphasis on the development of practical methods for the construction of enantiomerically pure cyclic systems. In this three-part scries, we will cover the most important recent advances. 

The U.S. Food and Drug Administration (FDA) approved 22 new drugs and one biotech medicine during 1994. These new drug entities had an adjusted average review time of 19.7 months, from filing of the New Drug Application (NDA) at the FDA to time of approval. This was down from the 25.6 months for the 26 new entities approval in 1993. In the total... 

Bittner, B. and R. J. Mount eld (2002). Intravenous administration of poorly soluble new drug entities in early drug discovery the potential impact of formulation on pharmacokinetic parameter 3D pin. Drug Disc. Develop., 5 59-71. 

Are stress-testing studies, the data from which may be included in the regulatory submission for a new drug entity, considered GMP studies ... 

A number of drugs reach a delicate state of patent by 2005. Therefore, an alternative is required for new drug development the formulation of drugs into separate delivery mechanisms, often known as drug delivery systems. Clearance for these innovative formulations as abbreviated new drug applications (ANDA) is easier, compared with a new drug entity that requires approval of the United States Food and Drug Administration (USFDA). 

A general trend in the pharmaceutical industry is to switch from racemates to single enantiomers. Examples are given by (i )-(-)-verapamil, (S)-fluoxetin, (S)-keto-profen, (R)-albuterol, levofloxacin, esomeprazole (see Chapter II-2), levocetirizine, and many others [17,18]. In addition to the quality improvement of the drug, this switch represents also a way to prolong its life insofar that the isolated eutomer is legally considered as a new drug entity. 

The following sections will detail approaches and options to assessing physiological functions as part of the overall safety assessment of new drug entities. 

Advance planning with development personnel can begin in many different ways. Typically, a project planning committee defines key stages in a new drug entity s life cycle. The committee will usually include the QA professional as a part of the team, which allows him or her to arrange a plan for monitoring the development life cycle from concept to submission. 

---